Markers of hypercoagulability and risk of death and rehospitalization in heart failure patients: a pilot study on the effects of Fondaparinux - Fondaparinux and heart failure

AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI0 个研究点开始时间: 2008年7月18日最近更新: 2014年3月10日

试验速览

暂无简介。

•Diagnosis of heart failure according to the Framingham criteria(III-IV NYHA) patients aged ≥ 60 years Patients with a planned hospital stay of at least 4 days
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Ischemic or haemorrhagic stroke within 12 months prior to admission; Creatinin clearance < 20 ml/min; Cerebral metastasis; Acute bacterial endocarditis; neoplastic or connective tissue disease; a recent history(3 months) of brain, spinal, or ophthalmological surgery; an indwelling intrathecal or epidural catheter; oral anticoagulant therapy; an indication for anticoagulant prophylaxis or therapy; life expectancy of less than one month; use of any experimental drug within 30 days before admission; major psychiatric disorders; Abuse of alcohol and / or drugs in the last year.

发起方

AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI